Inflammation biomarkers and risk of pulmonary hypertension: a Mendelian randomization study Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
CFTR and risk of pulmonary arterial hypertension: a case report and mendelian randomization study Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study Source: Eur Respir J, 58 (6) 2100848; 10.1183/13993003.00848-2021 Year: 2021
Cardio metabolic traits and lung function: A Mendelian Randomization study Source: International Congress 2018 – Role of omics in population studies Year: 2018
Age at menopause and lung function: A Mendelian randomization study Source: International Congress 2018 – Role of omics in population studies Year: 2018
Age at menopause and lung function: a Mendelian randomisation study Source: Eur Respir J, 54 (4) 1802421; 10.1183/13993003.02421-2018 Year: 2019
Altered gut microbiota in chronic thromboembolic pulmonary hypertension Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021
Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension Source: Eur Respir J, 55 (2) 1901486; 10.1183/13993003.01486-2019 Year: 2020
Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study Source: Eur Respir J, 52 (1) 1800766; 10.1183/13993003.00766-2018 Year: 2018
Pulmonary arterial hypertension-associated changes in gut pathology and microbiota Source: ERJ Open Res, 6 (3) 00253-2019; 10.1183/23120541.00253-2019 Year: 2020
Tobacco consumption, systemic inflammation, and airflow limitation: a Mendelian randomization analysis of 98085 individuals Source: International Congress 2018 – Novel findings in biomarkers of tobacco use, exposure, hazards and genetics Year: 2018
Late Breaking Abstract - The effect of altering gut microbiota on the development of pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities Year: 2019
Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study Source: Eur Respir J, 54 (4) 1900897; 10.1183/13993003.00897-2019 Year: 2019
Variation in mortality from pulmonary hypertension by aetiology Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Lung perfusion in pulmonary hypertension – results from the RESPIRE study Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020
Fluid challenge test during heart catheterization in normal subjects and in a heterogeneous population with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
Pulmonary hypertension due to lung disease – Results from COMPERA Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016